10-Q quarterly report · filed Nov 9, 2026

Coherus Oncology, Inc. (CHRS) Q3 2026 10-Q Quarterly Report

Short answer

Coherus Oncology, Inc. (CHRS) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $14M (up 23.4% year over year) with net income of −$39M.

Q3 2026 key financials · XBRL

Revenue
$14M
+23.4% YoY · −0.2% QoQ
Net income
−$39M
−10.7% YoY · −90.7% QoQ
Operating margin
-235.7%
EPS (diluted)
−$0.26
+16.1% YoY · −116.7% QoQ

Source: XBRL data from the Coherus Oncology, Inc. (CHRS) Q3 2026 10-Q on SEC EDGAR. USD.

Coherus Oncology, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $14.3M, up $2.7M YoY from $11.6M, driven by LOQTORZI volume growth
  • LOQTORZI best-performing product: revenue $14.0M vs $11.2M YoY
  • Gross margin figures not disclosed; operating profitability pressured by $3.4M debt extinguishment loss
  • Cash and investments $83.6M vs $172.1M at December 31, 2025; operating cash use $154.0M
  • 2026 revenue expected higher, but substantial doubt remains about continuing as a going concern within one year

Risk Factors

  • Newly emphasized going-concern risk: $83.6 million liquidity and $1.5 billion accumulated deficit after UDENYCA divestiture
  • Commercial risk: LOQTORZI faces penpulimab competition following its April 2025 FDA approval for nasopharyngeal carcinoma
  • Regulatory risk: OBBBA Medicaid funding reductions could reduce LOQTORZI sales through lower enrollment and coverage
  • Operational risk: U.S. onshoring of LOQTORZI, casdozokitug and tagmokitug manufacturing may face approval delays
  • Financial risk: UDENYCA earnouts are uncertain, with $37.5 million payments tied to $300 million and $350 million sales thresholds

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Coherus Oncology, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.